From the Journals

Aspirin’s Cancer Promise Questioned

A Cochrane review finds no reduction in colorectal cancer incidence during the first 15 years of aspirin use and confirms increased bleeding risk.

Share

Recent research published in the Cochrane Database of Systematic Reviews indicates that daily aspirin offers minimal reduction in colorectal cancer incidence over the first 15 years and may increase mortality associated with colorectal cancer within the initial 5 to 10 years. The study, which analyzed data from 10 randomized control trials with over 124,000 participants, reveals that while aspirin's impact on cancer incidence remains inconclusive, it significantly escalates the risk of serious extracranial hemorrhage. Consequently, healthcare professionals should consider individualized assessments before prescribing aspirin for colorectal cancer prevention.

Original Source(s)

Aspirin’s Cancer Promise Questioned

A Cochrane review finds no reduction in colorectal cancer incidence during the first 15 years of aspirin use and confirms increased bleeding risk.

  • by Kerri Miller

  • February 26, 2026

  • 5 min

Related Content

VA DOD Updates Asthma Framework

The 2025 US Department of Veterans Affairs and US Department of Defense asthma guideline introduces 21 evidence-based recommendations for primary care, redefining stepwise treatment, comorbidity management, and reliever strategy.

Primary Care’s Rug Pulled Out?

CMS abruptly scraps a 10-year primary care model, leaving nearly 700 practices rethinking staffing, funding, and patient access.

Can Primary Care Scale Any Further?

As primary care shortages deepen, health systems are testing AI-supported virtual care to maintain access.